Financial Knowledge & Information Portal

Dr. Reddy's Laboratories (RDY) Company Profile

Updated Oct 8, 2019
Dr. Reddy's Laboratories has the following business profile:
Company's Full Name:Dr. Reddy's Laboratories Ltd
Short Name:Dr. Reddy's Laboratories
Trading Ticker Symbol:RDY
Primary Exchange:NYSE
Headquarter City/Country:India
Primary Industry Sector:Health Care
Seconday Sub-sector:Major Pharmaceuticals
Main Business Areas: Health Care, Major Pharmaceuticals, Drug Manufacturers - Specialty & Generic, India
Dividend Payments:Dividend History

Market and Trading Information for Dr. Reddy's Laboratories

The following details were available for trading and market data about the stock of Dr. Reddy's Laboratories as of writing:
Current Share Price:$36.66
Previous Year's Closing Price:$37.7
Percentage Price Change (YTD):-2.76%
Market Cap:$6.15 billion
52-week Price Range:$31.69 - $42.82
Dividend Per Share:$20.06
EPS (TTM):1.4
Price-Earnings (Trailing):26.11
Price-Earnings (Forward):20.83

Company Profile and Business Description for Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, incorporated on February 24, 1984, is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities (NCEs). These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC. Others include the operations of its subsidiary, Aurigene Discovery Technologies Limited, a discovery-stage biotechnology company developing therapies in the fields of oncology and inflammation.

Global Generics segment

Global Generics segment includes the operations of its biologics business. The segment offers branded and unbranded drug products. Its Global generics segment includes various regions, such as India, Russia and Other Countries of the Former Soviet union, North America (the United States and Canada), Europe and Rest of the World markets. Its Rest of the World markets include Venezuela, South Africa and Australia. In India, the Company's therapeutic categories include gastro-intestinal, cardiovascular, pain management and oncology. It has also its presence in the areas of dermatology, urology and nephrology. As of March 31, 2016, the Company had a total of 296 branded products in India.

In Russia, the Company's brands include Nise, Omez, Ketorol and Cetrine. Omez is an anti-ulcerant product. Nise and Ketorol are pain management products. Cetrine is a respiratory product. In Russia, the Company is focused on the gastro-intestinal, pain management, anti-infectives, respiratory, oncology and cardiovascular therapeutic areas. The Company operates in other countries of the former Soviet Union, including Ukraine, Kazakhstan, Belarus, Uzbekistan and Romania. In the United States, the Company sells generic drugs that are the chemical and therapeutic equivalents of reference branded drugs. In Germany, it sells a range of generic pharmaceutical products under the betapharm brand. The Company markets its generic products in the United Kingdom and other European Union countries through its subsidiary, Dr. Reddy's Laboratories (U.K.) Limited.

Pharmaceutical Services and Active Ingredients segment

The Company's PSAI segment comprises its API business and Custom Pharmaceutical Services (CPS) business. It is also engaged in the manufacture and sale of steroids. The Company produces and markets over 100 different APIs for various markets. PSAI segment's API business is operated independently from its Global Generics segment and, in addition to supplying API to its Global Generics segment, PSAI segment sells API to third parties for use in manufacturing generic products. The Company exports API to over 80 countries, and principal overseas markets include North America (the United States and Canada) and Europe. API business also manufactures and supplies the API requirements of its pharmaceutical services business.

Proprietary Products segment

The Company has an internal pipeline of differentiated products in dermatology and neurology products in various stages of development. In addition, the Company has the commercial portfolio of in-licensed dermatology products. The Company's NCEs business is focused on the discovery, development and commercialization of small molecule agents in therapeutic areas, such as metabolic disorders, pain and inflammation. As of March 31, 2016, the Company had 19 active product development programs in its pipeline. The Company's products in Phase III development include DFN-02, DFD-01 (Sernivo), DFD-06, DFN-11 (Zembrace), DFD-09 (Zenavod), DFD-10, DFD-11 (Xeglyze), XP 23829 and E7777.

DFN-02 is used in acute treatment of migraines, with or without aura in adults. DFD-01 (Sernivo) is used to treat mild to moderate plaque psoriasis in patients of over 18 years of age. DFD-06 is used to treat moderate plaque psoriasis in patients over 18 years of age. DFN-11 (Zembrace) is used in aute treatment of migraine with or without aura in adults.

DFD-09 (Zenavod) is used in treatment of inflammatory lesions (papules and pustules) of rosacea in adult patients. DFD-10 is used to treat acne in patients of over 12 years of age. DFD-11 (Xeglyze) is used in the treatment of head lice in patients of over 6 months of age. XP 23829 is used to treat plaque psoriasis in patients of over 12 years of age. E7777 is used to treat Cutaneous T Cell Lymphoma.

Promius Pharma LLC has a portfolio of in-licensed patented dermatology products. It also has an internal pipeline of dermatology products that are in different stages of development Promius Pharma LLC's portfolio contains products for the treatment of seborrheic dermatitis, acne and steroid responsive dermatoses. It has commercialized six products: EpiCeram, a skin barrier emulsion for the treatment of atopic dermatitis; Scytera, a foam for the treatment of psoriasis; Promiseb, a cream for the treatment of seborrheic dermatitis; Cloderm, a cream used for treating corticosteroid-responsive dermatoses; Trianex, a cream for the treatment of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Zembrace SymTouch, an autoinjector for treatment of migraine headaches, and Sernivo, a spray for the treatment of mild to moderate plaque psoriasis. Promius Pharma LLC also markets and promotes Zenatane (isotretinoin).

The Company competes with Cipla Limited, GlaxoSmithKline Pharmaceuticals Limited, Cadila Healthcare Limited, Sun Pharmaceutical Industries Limited, Piramal Enterprises Ltd, Alkem Limited, Mankind Pharma Limited, Pfizer Limited, Abbott India, Lupin Limited, Aristo Pharma Limited, Intas Pharma, Sanofi India Limited, Emcure Pharmaceuticals Limited, Berlin Chemi AG, Gedeon Richter Limited, Krka d.d., Teva Pharmaceutical Industries Limited, Lek-Sandoz Pharmaceuticals, Ranbaxy Laboratories Limited, Nycomed International Management GmbH, Zentiva N.V., Mylan Inc., Novartis Pharma A.G., Endo Pharmaceuticals, Sun Pharmaceuticals Limited, Perrigo, Winthrop Arzneimittel GmbH, Stada Arzneimittel AG, Divis Laboratories Limited, Aurobindo Pharma Limited, Mylan Laboratories Limited, MSN Laboratories Limited, Dishman Pharmaceuticals & Chemicals Limited, Jubilant Organosys Limited, Nicholas Piramal India Limited, Lonza Group, Koninklijke DSM N.V., Albany Molecular Research, Inc., Patheon, Inc. and Cardinal Health, Inc.

8-2-337, Road No.3 Banjara Hills

Peer / Competitor Companies of Major Pharmaceuticals Sector

Along with Dr. Reddy's Laboratories Ltd, the following other peer (competitor) companies also exist within the same Major Pharmaceuticals - Health Care sector whose company profile and dividend history is as follows:

▶ Abbott Labs (ABT): Abbott Laboratories, incorporated on March 6, 1900, is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical ....See Detailed Company Profile  and Dividend History.

▶ AbbVie (ABBV): AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. ....See Detailed Company Profile  and Dividend History.

▶ Abeona Therapeutics (ABEO): Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., incorporated on June 22, 1989, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Companys lead ....See Detailed Company Profile  and Dividend History.

▶ Abeona Therapeutics (ABEOW): ....See Detailed Company Profile  and Dividend History.

▶ AC Immune SA (ACIU): AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimers and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinsons, and ....See Detailed Company Profile  and Dividend History.

▶ ACADIA Pharma (ACAD): ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. The ....See Detailed Company Profile  and Dividend History.

▶ Acasti Pharma (ACST): Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. The Company is involved ....See Detailed Company Profile  and Dividend History.

▶ AcelRx Pharma (ACRX): AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company ....See Detailed Company Profile  and Dividend History.

▶ Achaogen (AKAO): Achaogen, Inc., incorporated on November 26, 2002, is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative ....See Detailed Company Profile  and Dividend History.

▶ Achillion Pharma (ACHN): Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and ....See Detailed Company Profile  and Dividend History.

▶ Aclaris Therapeutics (ACRS): Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological ....See Detailed Company Profile  and Dividend History.

▶ Actinium Pharma (ATNM): Actinium Pharmaceuticals, Inc. (Actinium), incorporated on March 20, 2013, is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its ....See Detailed Company Profile  and Dividend History.

▶ Acura Pharma (ACUR): Acura Pharmaceuticals, Inc., incorporated on April 10, 1935, is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication ....See Detailed Company Profile  and Dividend History.

▶ Adamas Pharma (ADMS): Adamas Pharmaceuticals, Inc., incorporated on November 15, 2000, is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic ....See Detailed Company Profile  and Dividend History.

▶ Adamis Pharma (ADMP): Adamis Pharmaceuticals Corporation, incorporated on April 22, 2004, is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products ....See Detailed Company Profile  and Dividend History.

▶ Aduro Biotech (ADRO): Aduro Biotech, Inc., incorporated on May 5, 2011, is an immunotherapy company. The Company focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, ....See Detailed Company Profile  and Dividend History.

▶ Advanced Accelerator Applications (AAAP): Advanced Accelerator Applications S.A., incorporated on March 1, 2002, is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace ....See Detailed Company Profile  and Dividend History.

▶ Advaxis (ADXS): Advaxis, Inc., incorporated on February 28, 2002, is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are ....See Detailed Company Profile  and Dividend History.

▶ Advaxis (ADXSW): ....See Detailed Company Profile  and Dividend History.

▶ Aeglea BioTherapeutics (AGLE): Aeglea BioTherapeutics, Inc., incorporated on December 16, 2013, is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to ....See Detailed Company Profile  and Dividend History.

... See Full List of All Stocks of Major Pharmaceuticals Sector.

Stock List of Other Health Care Sub-sectors

▶ Stocks of Sector

▶ Stocks of Biotech Sector

▶ Stocks of Biotech Apparatus Sector

▶ Stocks of Biotech Diagnostics Sector

▶ Stocks of Biotech Products Sector

▶ Stocks of Biotech Research Sector

▶ Stocks of Drug Delivery Sector

▶ Stocks of Drug Development Sector

▶ Stocks of Drug Manufacturer Sector

▶ Stocks of Health Care Sector

▶ Stocks of Health Care Equipment and Services Sector

▶ Stocks of Hospital and Nursing Management Sector

▶ Stocks of Industrial Specialties Sector

▶ Stocks of Major Pharmaceuticals Sector

▶ Stocks of Medical Dental Instruments Sector

▶ Stocks of Medical Electronics Sector

▶ Stocks of Medical Nursing Services Sector

▶ Stocks of Medical Products Sector

▶ Stocks of Medical Specialities Sector

▶ Stocks of Ophthalmic Goods Sector

▶ Stocks of Other Pharmaceuticals Sector

▶ Stocks of Precision Instruments Sector

Stock List of Other Top-level Sectors

▶ Stocks of Sector

▶ Stocks of Basic Industries Sector

▶ Stocks of Basic Materials Sector

▶ Stocks of Capital Goods Sector

▶ Stocks of Communication Services Sector

▶ Stocks of Consumer Cyclical Sector

▶ Stocks of Consumer Defensive Sector

▶ Stocks of Consumer Durables Sector

▶ Stocks of Consumer Non-Durables Sector

▶ Stocks of Consumer Services Sector

▶ Stocks of Energy Sector

▶ Stocks of Finance Sector

▶ Stocks of Financial Services Sector

▶ Stocks of Health Care Sector

▶ Stocks of Industrials Sector

▶ Stocks of Miscellaneous Sector

▶ Stocks of Public Utilities Sector

▶ Stocks of Real Estate Sector

▶ Stocks of Services Sector

▶ Stocks of Technology Sector

▶ Stocks of Transportation Sector

▶ Stocks of Utilities Sector